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Several tumor necrosis factor receptor (TNFR) family members activate both the classical and the alter-
native NF-B pathways. However, how a single receptor engages these two distinct pathways is still poorly
understood. Using lymphotoxin  receptor (LTR) as a prototype, we showed that activation of the alternative,
but not the classical, NF-B pathway relied on internalization of the receptor. Further molecular analyses
revealed a specific cytosolic region of LTR essential for its internalization, TRAF3 recruitment, and p100
processing. Interestingly, we found that dynamin-dependent, but clathrin-independent, internalization of
LTR appeared to be required for the activation of the alternative, but not the classical, NF-B pathway. In
vivo, ligand-induced internalization of LTR in mesenteric lymph node stromal cells correlated with induction
of alternative NF-B target genes. Thus, our data shed light on LTR cellular trafficking as a process required
for specific biological functions of NF-B.
The tumor necrosis factor receptor (TNFR)/tumor necrosis
factor ligand (TNFL) superfamily forms a complex network of
cytokines and receptors that are important for biological func-
tions ranging from cell homeostasis and inflammation to lym-
phoid organ development (20). This family is subdivided ac-
cording to structural features within the cytosolic tail such as
the presence of a death domain (DD) and/or tumor necrosis
factor receptor-associated factor (TRAF) binding sites (6, 11).
The DD is involved in the recruitment of other death domain-
containing proteins like FADD and TRADD, which connect
the receptor to downstream signaling pathways leading to cell
death or cell survival. Likewise, the recruitment of adaptor
protein TRAF triggers both mitogen-activated protein kinase
(MAPK) and NF-B signaling pathways. Two consensus bind-
ing sites for TRAF2, (P/S/A/T)X(Q/E)E and PXQXXD, and
one for TRAF3, PXQX(S/T), have been defined based on
alignment of TNFR family members (11, 57). However, non-
canonical TRAF binding sites have also been identified for
other substrates, such as NF-B-inducing kinase (NIK) or
TRADD (30, 38). TRAF proteins connect TNFR to at least
two NF-B signaling pathways. The first, named the classical
(or canonical) NF-B pathway, is activated by most TNFRs.
Our current understanding is that TRAF proteins are recruited
directly or indirectly (e.g., through TRADD for TNFR1) to
TNFR, which then recruits the IB kinase (IKK) complex that
is targeted for posttranslational modifications impinging on its
catalytic activity (51). Among those, autophosphorylation of
IKK takes place shortly after TNFR engagement (10), while
the regulatory subunit NEMO (or IKK) seems to be modified
by both K63 and linear polyubiquitination (22). Then, the IKK
complex phosphorylates IB proteins to trigger their protea-
somal degradation and the release of related NF-B dimers.
The latter control many of the proinflammatory and antiapo-
ptotic roles associated with NF-B through binding to a spe-
cific cis regulatory region called the B site (37, 39).
An additional biological outcome accounts for TNFR mem-
bers by the fact that a subclass (e.g., TNFRI and HVEM)
activates solely the classical NF-B pathway whereas other
TNFRs (e.g., lymphotoxin  receptor [LTR] and CD40) ac-
tivate both the classical and the alternative (or noncanonical)
NF-B pathways (8, 51). The alternative pathway involves the
activation of the NF-B-inducing kinase (NIK), which acti-
vates IKK, and both phosphorylate the inhibitor p100, lead-
ing to its subsequent polyubiquitination and partial protea-
somal degradation into p52 (46, 56). In particular, it was
demonstrated that neither LTR nor BAFF-R required
NEMO or IKK for inducing p100 processing (7–9). Ulti-
mately, NIK and IKK activate the dimer p52/RelB, which
controls a set of genes involved in secondary lymphoid organ
development, B cell survival, and osteoclastogenesis (45, 53).
Indeed, NIK- and IKK-deficient mice share a panel of devel-
opmental abnormalities reminiscent of mice deficient in
LTR, BAFF-R, or RANK (13, 15, 25, 46, 47, 49, 58). Dereg-
ulation of the alternative NF-B pathway has also been asso-
ciated with malignancy. For instance, transgenic mice express-
ing inducers of the alternative pathway such as BAFF or
LT12 display lymphoid malignancies and hepatocellular
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carcinoma development, respectively (2, 18, 28). On the other
hand, elevated expression of NIK and/or loss of expression of
its negative regulators is a signature found in multiple my-
eloma and B cell lymphoma (1, 26, 42).
Thus, NIK appears to play a central role in many biological
functions, but the molecular determinants that dictate its ac-
tivation are still poorly characterized. The current model de-
picts TRAF3 as a bridge between TRAF2-associated c-IAP1/2
E3 ligase complex and the N-terminal domain of NIK promot-
ing its constitutive K48-linked polyubiquitination and protea-
somal degradation. Upon stimulation of CD40, TRAF3 is
polyubiquitinated by c-IAP1/2 and degraded by the protea-
some, allowing the stabilization and accumulation of NIK (30,
52, 60). Hence, TRAF3 recruitment has been proposed as a
hallmark of the TNFR-induced alternative NF-B pathway
(17). However, HVEM, a TNFR that binds TRAF3, fails to
activate the alternative pathway (5, 33). Thus, it is likely that
the capacity to recruit TRAF3 is necessary but not sufficient for
inducing the alternative NF-B pathway.
Thus, the molecular mechanisms linking the outcome of
TRAF-associated TNFR and the activation of p100 processing
are far from being fully understood and need further biochem-
ical and biological characterization. In this study, we have
addressed how LTR activates both the classical and the al-
ternative NF-B pathways. We found that activation of these
two pathways is spatially and temporally regulated by LTR
trafficking.
MATERIALS AND METHODS
Plasmids, cloning, and mutagenesis. Expression vectors and sequences of
primers used for cloning and mutagenesis are available upon request. PCR
amplification of cDNAs was performed with Goldstar DNA polymerase (Euro-
gentec), and mutagenesis of LTR was performed using the QuikChange site-
directed mutagenesis XL kit (Stratagene) according to the manufacturer’s in-
structions.
Abs and reagents. The following commercially available antibodies (Abs) were
used for several applications: p100/p52 (05-361) and anti-ubiquitin Lys48-specific
antibody (05-1307) from Millipore; phospho-p100 (4810), phospho-IB (9246),
anti-NIK (4994), and Myc tag (2276) from Upstate Cell Signaling; antihemag-
glutinin (anti-HA) (sc-805), LTR-N15 (sc-8375), TRAF2 H-249 (sc-7187),
TRAF3 H-122 (sc-1828), TRAF3 H-20 (sc-948-G), TRAF5 H-257 (sc-7220), and
clathrin heavy chain (CHC) (sc-12374) from Santa Cruz Biotechnology; actin
(69100) from MP Biomedicals; HA (MMS-101R) from Covance; Flag M2
(F3165) and Beads Red anti-Flag M2 (F2426) from Sigma; h-LTR (AF629)
from R&D Systems; glutathione S-transferase (GST) tag (71097-3) from Nova-
gen; EEA1 (610456); AP50 (612620) from BD Bioscience; anti-dynamin-2 (PA1-
661) from Thermo Scientific; and anti-NIK (ab8111) from Abcam.
Anti-IB monoclonal antibody (MAb) 10 was a gift from Ron Hay (Univer-
sity of St. Andrews, St. Andrews, Scotland). Anti-murine LTR, mICAM-1,
mVCAM-1, mMAdCAM-1, CD45, and mp100/p52 were previously described (3,
9). The following reagents were purchased from the indicated companies: chlo-
roquine (C6628), bafilomycin A1 (B1793), N-ethylmaleimide (E1271), and n-oc-
tyl--D-glucopyranoside (29836-26-8) from Sigma; dithiobis[succinimidyl propi-
onate] (DSP) (22585) from Thermo Scientific; recombinant LT12 (678-LY)
from R&D Systems; digitonin (300410) from Calbiochem; and Topro-3 iodide
from Invitrogen.
Mice and lymph node explants. C57BL/6 (H-2b) and RelB/ (H-2b) mice
(backcrossed for more than 10 generations in a C57BL/6J background) (54) were
bred and maintained under specific-pathogen-free conditions in the Biomedical
Service Unit at the University of Birmingham according to Home Office and
local ethics committee regulations. The day of vaginal plug detection was des-
ignated E0. Freshly isolated fetal lymph nodes were isolated at the indicated time
and either analyzed directly or explanted in organ cultures and incubated for 72 h
in the presence of an agonistic antibody to LTR at 2 g/ml (3).
Cell lines, transfection, and retroviral infection. HEK 293, HEK 293T, HeLa,
and HeLa Tet/On Advanced (Clontech) cells and LTR knockout (KO) MEFs
were grown in Dulbecco modified Eagle medium (DMEM) supplemented with
10% fetal bovine serum (FBS), 1% antibiotics, and 1% L-glutamine. For tran-
sient transfections, cells were seeded at 70 to 80% confluence and transfected
using Lipofectamine 2000 (Invitrogen) or Fugene HD (Roche Applied Sciences).
For analyzing LTR-mediated p100 processing into HEK 293T cells, 6-well
plates were used and 100 ng of LTR expression vector was transfected per well.
Retrovirus was collected from the supernatant of Phoenix Ampho packaging
cells transfected with pRetroX-Tight-HA-2-D176A/W421A or pBabe-puro-
LTR encoding wild type (wt) or I 389–395, I 345–358, or I 359–368 mutant
and used to infect HeLa Tet/On and HEK 293T cells or LTR KO MEFs,
respectively. Single clones were obtained after antibiotic selection, and expres-
sion of AP22-DN (dominant negative) was achieved by adding 2 g/ml of
doxycycline for the indicated period.
siRNA knockdown experiments. Knockdown experiments for targeting CHC
or Dyn2 in HeLa cells were carried out with On Target Plus Smart pools
M-004001 and L-004007, respectively (Dharmacon). The experiments were per-
formed according to the protocol described by Motley et al. with minor modifi-
cations (36). HeLa cells were transfected with either small interfering RNA
(siRNA) green fluorescent protein (GFP) as negative control or siRNA CHC.
For the first round of transfection, cells were plated in 6-cm dishes and incubated
for 4 h in serum/antibiotic-free medium in the presence of 12 l Oligofectamine
(Invitrogen) and 120 pmol of siRNA. Cells were trypsinized 24 h posttransfection
and seeded into a 10-cm dish. After the second round of transfection on day 3,
the cells were split into 6-well plates for further analyses on day 5. Knockdown
experiments for targeting human AP22 in HeLa Tet/On rat AP22-DN were
performed with two siRNAs (GCGAGAGGGUAUCAAGUAU and AGUUU
GAGCUUAUGAGGUA) designed to efficiently target human AP22 but not
rat AP22-DN (J-008170; Dharmacon). The cells were transfected twice, on day
1 and day 3, with siRNA AP22 or with GFP siRNA as negative control
(Dharmacon). Doxycycline was added at 2 g/ml in the medium over the 5 days
of the experiment.
Immunoblotting, IP, and cell extract fractionation. Whole-cell extracts were
prepared by lysing cells in 0.5% SDS containing 5 mM sodium fluoride (NaF), 1
mM sodium orthovanadate (Na3VO4), 20 mM -glycerolphosphate (GP), and
Complete protease inhibitor (Roche). Cell extracts were separated by SDS-
PAGE and transferred onto nitrocellulose membranes (Millipore) followed by
incubation with specific primary antibodies and secondary horseradish peroxi-
dase (HRP)-conjugated antibodies (Dako). For coimmunoprecipitation (co-IP)
assays, cells were analyzed after stimulation with LTR antibody or 40 h post-
transfection. Cells were lysed in TNT buffer (20 mM Tris-HCl, pH 7.4, 200 mM
NaCl, 0.5 to 1% Triton X-100, 5 mM NaF, 1 mM Na3VO4, 20 mM GP, and
Complete protease inhibitor). After a preclearance of 1 h with protein A agarose
beads, cell lysates were incubated overnight with the indicated antibodies and
with protein A or G agarose beads for an additional hour. For double immuno-
precipitation (IP), an excess of 3 Flag peptide was used overnight to release the
Flag-immunoprecipitated material and a second immunoprecipitation was car-
ried out with either an anti-HA or an anti-Myc antibody. The agarose beads were
washed four times with TNT buffer before addition of 4 loading buffer. Sam-
ples were then subjected to SDS-PAGE. In order to determine the presence of
LTR mutants in detergent-insoluble fraction, HEK 293T cells were lysed 40 h
posttransfection in 0.5% Triton-TNT buffer for 15 min on ice. Supernatants
corresponding to detergent-soluble fraction were isolated after centrifugation at
13,200 rpm for 15 min. The pellets corresponding to the detergent-insoluble
fraction were resolubilized by sonication in octylglucoside-containing buffer (60
mM n-octyl--D-glucopyranoside, 150 mM NaCl, 20 mM Tris-HCl, pH 7.4, 1%
Triton X-100, 0.1% SDS, 5 mM NaF, 1 mM Na3VO4, 20 mM GP, and Com-
plete protease inhibitor). After incubation for 30 min on ice, the detergent-
insoluble lysates were clarified by centrifugation at 13,200 rpm for 15 min at 4°C.
Samples were analyzed by immunoblotting for LTR expression.
For studying the formation of K48-linked polyubiquitination, we transfected
293T cells. Thirty-six hours posttransfection, cells were incubated for 6 h with the
proteasome inhibitor MG132 prior to lysis under denaturing conditions with
0.5% SDS. Following clearance of cell extracts and dilution up to 0.1% (final
concentration) SDS, we performed two sets of immunoprecipitations for assess-
ing the K48-linked polyubiquitination of both TRAF3 and NIK. Cells transfected
with NIK, TRAF2, TRAF3, and HA-ubiquitin or the same combination in
addition to LTR S were lysed, and equal amounts of cell extracts were used
for immunoprecipitation with either control IgG or anti-TRAF3 antibodies (1st
IP). Following incubation with protein A agarose beads, the supernatants were
kept for a second round of immunoprecipitation (2nd IP) whereas the immuno-
precipitates were loaded on a Western blot for the detection of TRAF3 and
K48-linked polyubiquitinated TRAF3. On the other hand, the second set of
immunoprecipitations (2nd IP) was carried out with supernatants from the first
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immunoprecipitation experiment (1st IP) by incubation with either control beads
or Flag-M2 beads. The immunoprecipitates were then used for detecting Flag-
NIK and K48-linked polyubiquitinated NIK. Quantification of signals was per-
formed with the Image J software.
Oligomerization of LTR and GST pulldown. For studying the ability of
LTR to form trimers, we performed transient transfections of HEK 293T cells
with a combination of HA-, Flag-, and Myc-tagged LTR expression vectors. A
first immunoprecipitation was performed using Flag-M2 agarose beads. The
immunoprecipitated material was then selectively released overnight by compe-
tition with an excess of 3 Flag peptide (Sigma). The supernatants were sub-
jected to a second immunoprecipitation with either an anti-HA or an anti-Myc
antibody for 2 h at 4°C. The immunoprecipitated materials were analyzed by
immunoblotting with an anti-Myc or an anti-HA antibody, respectively. To an-
alyze aggregation of ectopic LTR, HEK 293T cells were collected 40 h post-
transfection, washed twice with phosphate-buffered saline (PBS), and then in-
cubated for 30 min at room temperature in PBS containing 1 mM
dithiobis[succinimidyl propionate] (DSP; Pierce/Thermo Fisher Scientific). After
cross-linking, the cells were washed once in PBS and incubated for 15 min in 20
mM Tris-HCl (pH 7.4)–PBS to stop the reaction. The cells were scraped in SDS
buffer, and protein extracts were analyzed by immunoblotting for LTR expres-
sion. pGEX-4T1-wt LTR or mutant expression vectors were transformed into
Escherichia coli BL21. Bacterial cultures were grown to an A600 of 0.6 and were
induced with 0.5 mM isopropyl--D-thiogalactopyranoside for 4 h at 37°C. After
washing in PBS, the bacterial pellets were sonicated in NENT buffer (250 mM
NaCl, 1 mM EDTA, 20 mM Tris-HCl, pH 8, 1.5% Nonidet P-40). The lysates
were cleared by centrifugation and incubated with glutathione-Sepharose 4B
beads for 1 h at 4°C. After three washes in NENT buffer, the beads were
collected in TWB buffer (20 mM HEPES, pH 7.9, 60 mM NaCl, 1 mM dithio-
threitol [DTT], 6 mM MgCl2, 8.2% glycerol, 0.1 mM EDTA). Expression of GST
fusion proteins was estimated by SDS-PAGE and Coomassie blue staining. 35S
labeling of TRAF proteins was generated in vitro using the TNT kit from
Promega. For GST fusion protein interactions with 35S-TRAF proteins, an
aliquot of glutathione-Sepharose beads containing 1 g of GST fusion protein
was incubated with 7.5 l of in vitro-translated TRAF for 1 h at 4°C in NENT
buffer. Beads were washed five times in NENT buffer and then boiled in SDS
loading buffer for 5 min. Bound proteins were analyzed by SDS-PAGE and then
by autoradiography. For analyzing the binding of overexpressed mammalian
TRAF proteins, cell lysates were prepared from transfected 293T cells in TGH
buffer (50 mM HEPES, pH 7.4, 1% Triton X-100, 10% glycerol, 100 mM NaCl,
1 mM EDTA, 1 mM EGTA, 1 mM phenylmethylsulfonyl fluoride [PMSF], and
protease inhibitors). One microgram of GST fusion protein was incubated with
150 g of cell lysates for 3 h at 4°C. Beads were washed five times in TGH buffer
and then boiled in SDS loading buffer for 5 min. Bound proteins were analyzed
by SDS-PAGE and immunoblotting.
Flow cytometry. LTR-expressing HEK 293 cells were analyzed 2 days post-
transfection. Cells were fixed in 1% paraformaldehyde, permeabilized or not
with 0.5% saponin, and incubated for 30 min with an anti-LTR antibody. After
washing in PBS-bovine serum albumin (BSA), cells were stained with a goat
anti-LTR and a donkey anti-goat antibody–phycoerythrin (PE). To study the
internalization of LTR in MEFs or in HT29 cells, the cells were stimulated with
2 g/ml of agonistic antibody to murine LTR or 0.2 g/ml of agonistic antibody
to human LTR and were incubated for the indicated period of time. After
collection of the cell, the staining of cell surface and internalized LTR was
achieved with the same agonistic antibody followed by incubation with PE-
labeled goat anti-rat secondary antibody or PE-labeled donkey anti-goat anti-
body. Samples were analyzed on a FACSCanto II flow cytometer (BD Biosci-
ences), and at least 10,000 events were acquired for each sample using
FACSDiva6 software (BD Biosciences). Staining of mesenteric lymph node
(mLN) stromal cells was performed as previously described (3).
Immunofluorescence microscopy. Transfected HEK 293T or HeLa cells were
grown on glass coverslips. Two days posttransfection, cells were fixed in 4%
paraformaldehyde for 30 min and permeabilized with 0.5% saponin-PBS for 20
min. 293T cells were then incubated for 1 h with anti-human LTR antibody and
subsequently incubated for 50 min with a donkey anti-goat antibody–Alexa 546
(Invitrogen). Nuclei were stained with Topro-3 iodide (Invitrogen).
Transfected HeLa cells with HA-tagged wt LTR, S-LTR, and S I
345–358 LTR were stained with anti-HA sc-805 at a 1/50 dilution and an
anti-rabbit antibody–Alexa 546, and nuclei were visualized with 4	,6-diamidino-
phenylindole (DAPI). For the colocalization of LTR and endosomes, staining
was performed on HT29 cells treated with the agonist antibody to LTR. Fol-
lowing the indicated kinetic of stimulation, cells were fixed for 20 min with 2%
of p-formaldehyde and permeabilized for 15 min at room temperature with 50
M digitonin. LTR was detected with agonist primary antibody and a donkey
anti-goat secondary antibody–Alexa 546. Early endosomes were detected with a
mouse monoclonal anti-EEA1 antibody and a donkey anti-mouse-Alexa 488
secondary antibody.
Localization of endogenous TRAF3/NIK complex was achieved using the
Duolink II Orange kit (Eurogentec, Belgium). Anti-rabbit plus and anti-goat
minus antibodies were used as secondary antibodies for recognition of anti-
TRAF3 H-20 (sc-948-G; Santa Cruz Biotechnology) and anti-NIK (ab8111;
Abcam), and polymerase reaction was performed for 150 min. Nuclei were
visualized with DAPI. Confocal microscopy was performed with either a Leica
TCS SP2 microscope or an Olympus FV1000 microscope.
RESULTS
Molecular determinants of LTR involved in induction of
p100 processing. It has been previously shown that overexpres-
sion of LTR is sufficient to activate NF-B in a ligand-inde-
pendent way (14). We constructed a panel of deletion mutants
of the cytosolic tail of LTR and evaluated their ability to
induce the processing of p100 (Fig. 1A). All deletion mutants
expressing at least the first 395 amino acids induced the pro-
cessing of p100, whereas the shorter mutants did not (Fig. 1B).
Thus, removal of the six residues upstream of amino acid 389
was sufficient to prevent LTR-induced p100 processing. This
region was characterized as a TRAF binding region involved in
NF-B activation (14). We narrowed down the critical region
up to amino acid 392 (see Fig. S1A in the supplemental ma-
terial). Surprisingly, alteration of acidic amino acids crucial for
the recruitment of TRAF proteins into alanine (29) or internal
deletion from amino acid 389 to 395 did not abrogate LTR-
induced p100 processing (Fig. 1C). Titration of wt LTR and
LTR I 389–395 expression level indicated that this TRAF
binding site was dispensable for the induction of p100 process-
ing (see Fig. S1B). These results suggested the requirement of
another region upstream of amino acid 392 for LTR-medi-
ated p100 processing. Bioinformatics analysis of the cytosolic
tail revealed another putative TRAF3 binding site, PQQQS, at
position 319 to 323 matching the consensus PXQX(S/T). How-
ever, the substitutions Q321A and S323A did not inhibit
LTR-induced p100 processing (see Fig. S1C). By generating
additional internal deletions, we identified two mutants,
named I 345–358 and I 359–368, missing critical regions for
the processing of p100 (Fig. 1D). Additional shorter internal
deletions along the region 345 to 368 displayed an alteration
of LTR-induced p100 processing to the same extent as I
345–358 and I 359–368 mutants (see Fig. S1D). In order to
confirm our results under physiological conditions, we gen-
erated 293T clones stably expressing wt and mutant LTR
for which ligand inducibility was maintained (Fig. 1E).
While agonistic anti-LTR treatment allowed the induction
of p100 processing in wt and I 389–395 LTR-expressing
cells, cells expressing I 345–358 LTR failed to respond
(Fig. 1F and data not shown). Similar results were obtained
when we complemented LTR KO MEFs with the same
expression vectors (see Fig. S1E and F).
Conformation of LTR dictates the avidity of its bipartite
binding sites toward specific TRAF proteins. So far, a single
TRAF binding site has been characterized and located at po-
sition 387 to 396 of human LTR (14, 29). However, we dem-
onstrated that this region was dispensable for the induction of
the alternative NF-B pathway (Fig. 1C). Therefore, we hy-
pothesized that LTR may contain another TRAF binding site
required for the induction of p100 processing. We analyzed the
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FIG. 1. Identification of the cytoplasmic domain involved in LTR-mediated p100 processing. (A) Schematic representation of human
full-length and deletion mutant LTR. The black bar, the gray bar, and TM represent the extracellular domain (amino acids 1 to 121), the
cytosolic tail (amino acids 242 to 425), and the transmembrane domain (amino acids 222 to 241), respectively. (B to D) HEK 293 cells were
transiently transfected with different sets of LTR deletion mutants of the cytosolic tail and with the triple D390D391E393/AAA mutant.
(E) 293T cells were stably infected with retrovirus encoding the indicated Myc-tagged LTR, and expression was analyzed with anti-Myc
immunoblotting. (F) Stable clones were stimulated for 6 h with an agonistic (Ago) anti-LTR antibody prior to analysis by Western blotting
of the processing of p100 into p52.
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recruitment of in vitro-translated 35S-TRAF2 and 35S-TRAF3
with recombinant GST-LTR. We detected TRAF association
with wt GST-LTR but not with the mutant GST-LTR-AAA,
which contains point mutations disrupting TRAF recruitment
within the region 387 to 396 (29) (Fig. 2A). Similarly, both
GST-I 345–358 and GST-I 359–368 failed to bind in vitro-
translated TRAF proteins or HA-TRAF3-containing 293 cell
extracts (and TRAF2) (data not shown). Thus, the amino acid
stretch 345 to 368, similarly to the region 387 to 396 of human
LTR, is required for the binding of TRAF proteins when
FIG. 2. Conformation of LTR dictates the mechanism of TRAF recruitment through an unconventional bipartite site. (A) GST pulldown of
either in vitro-translated TRAF2 and TRAF3 or 293 cell extracts containing HA-TRAF3 with GST-LTR and the indicated mutants. (B) Align-
ment of human and mouse LTR. The two TRAF binding sites are boxed with dashed lines. (C and D) HEK 293T cells were transfected with
internal deletion mutant LTR, and immunoprecipitated LTR was analyzed by Western blotting for the recruitment of TRAF2 and TRAF3
(C) or ectopic Flag-TRAF5 (D).
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expressed as GST fusion proteins. Analysis of amino acid con-
tent of the region 345 to 368 did not reveal any conserved
consensus TRAF binding site within either mouse or human
LTR (Fig. 2B). When we overexpressed wt and mutant LTR
into 293 cells, we observed that disruption of the region 389 to
395, 378 to 388, 359 to 368, or 345 to 358 completely abolished
the recruitment of TRAF2 and TRAF5. However, removal of
the regions 389 to 395 and 378 to 368 did affect the recruitment
to TRAF3, but a significant residual binding was still observed
despite this deletion (Fig. 2C and D). Hence, on one hand,
when the cytosolic tail of LTR is fused to GST, any mutation
or deletion within one of the two TRAF binding sites is suffi-
cient to abrogate the binding of TRAF2 or TRAF3. On the
other hand, when full-length LTR is expressed in 293 cells,
the region 345 to 358 is sufficient for the recruitment of
TRAF3 and the induction of p100 processing.
Internalization of LTR is required to induce the process-
ing of p100. Trimerization of TNFR is a prerequisite for trig-
gering their downstream pathways. Thus, we addressed
whether the LTR mutants deficient for the induction of p100
processing were able to trimerize. We transfected 293 cells
with three differently tagged wt or mutant LTR I 345–358
and I 359–368 constructs (Flag, HA, and Myc). The resulting
cell lysates were subjected to a double immunoprecipitation
(IP) procedure (see Materials and Methods), and the immu-
noprecipitated materials were analyzed by Western blotting for
expression of the third tagged LTR. Under those conditions,
wt LTR was able to trimerize (Fig. 3A; see also Fig. S3A in
the supplemental material). Interestingly, mutants LTR I
345–358 and I 359–368 were still able to form trimeric com-
plexes, while other TNFR-related proteins, such as Trail-R3
and TNFRII, did not coimmunoprecipitate (co-IP) in single-IP
or double-IP procedures (Fig. 3B; see Fig. S3B). We also
analyzed the ability of wt LTR and mutants I 345–358, I
359–368, and 389 to form aggregates upon overexpression in
293 cells. Thirty-six hours posttransfection, cells were cross-
linked with a membrane-permeable cross-linker (DSP) and
LTR aggregation was analyzed by Western blotting in the
absence or presence of DTT (reversed cross-link). All mutants
defective for p100 processing were as efficient as wt LTR in
forming high-molecular-weight aggregates (Fig. 3C). Overall,
our data showed that deletions I 345–358 and I 359–368 did
not affect the ability of LTR to multimerize. Meanwhile,
when we monitored by flow cytometry the outcome of cell
surface expression of wt and mutants I 345–358 and I 359–
368 in both nonpermeabilized (NP) and permeabilized (P) 293
transfected cells, we observed striking differences. As expected,
a pool of wt LTR was detected at the cell surface of nonper-
meabilized 293 cells. However, the intensity of fluorescence
was elevated in permeabilized cells, indicating that part of wt
LTR was present within an intracellular compartment (Fig.
3D). In contrast, both LTR mutant I 345–358 and mutant
I 359–368 were exclusively localized at the cell surface, since
no further increase of fluorescence intensity was detected upon
cell permeabilization. We confirmed by confocal microscopy
that wt LTR displayed a perinuclear staining whereas both
mutant I 345–358 and mutant 
 359–368 were exclusively
seen in the plasma membrane (Fig. 3E). We also analyzed by
Western blotting the cellular distribution into soluble and in-
soluble Triton X-100 fractions of active wt LTR and LTR-
AAA and inactive I 345–358 and I 359–368 LTR, for the
processing of p100. Our results revealed that internalized wt
LTR and LTR-AAA were mainly present in the insoluble
fraction while the mutants I 345–358 and I 359–368 were
mainly found in the soluble fraction (Fig. 3F).
We next explored the ability of LTR to recruit TRAF2 and
TRAF3 from the intracellular compartment. We first con-
structed signal sequence-deficient (S) expression vectors for
wt LTR, I 345–358, and I 359–368 and checked their
cellular localization in nonpermeabilized (NP) and permeab-
ilized (P) cells. In all cases, we detected LTR expression only
in permeabilized cells, confirming the inability of LTR to
migrate to the cell surface (Fig. 4A). We then looked at the
cellular location of these signal sequence-defective mutants by
confocal microscopy. We observed a punctate staining of
LTR S wt mainly localized in the perinuclear compartment.
However, the staining was largely diffuse when the region 345
to 358 of LTR was absent, indicating that this stretch of the
receptor directs its specific intracellular location (Fig. 4B). We
then showed that LTR S wt could recruit endogenous
TRAF2 and TRAF3 as wt LTR. However, the recruitment
was impaired in the absence of the region 345 to 358 or 359 to
368 irrespective of the presence of the signal sequence (Fig.
4C). These results highlight a dual role of the region 345 to 368
of LTR in mediating internalization from the plasma mem-
brane (Fig. 3D and E) and TRAF recruitment from an internal
cellular compartment. In addition, we observed that the ability
of LTR S wt to induce the processing of p100 was severely
impaired for the mutants S/I 345–358 and S/I 359–368
(Fig. 4D).
Overall, our results reveal that internalization of LTR and
binding of intracellular TRAF2 and TRAF3 are a prerequisite
for the induction of p100 processing.
Internalization of LTR in vivo correlates with induction of
the alternative NF-B pathway. We next addressed the phys-
iological relevance of our findings in biological settings for
which an LTR-induced alternative pathway is known to play
a role through production of p52/RelB. Therefore, we isolated
mesenteric lymph nodes (mLNs) from embryonic day 14 (E14)
from wt and RelB-deficient mice and explanted them ex vivo in
fetal organ culture. At that stage, mLN stromal cells had not
yet fully matured and most CD45 cells were ICAM-1int
VCAM-1int (3). However, treatment of wt explants with an
agonistic antibody to LTR for 3 days allowed ICAM-1int
VCAM-1int cells to commit into ICAM-1high VCAM-1high ma-
ture stromal “organizer” cells (Fig. 5A). During the maturation
process, these cells expressed MAdCAM-1 at a high level.
Interestingly, this transition was abrogated in mLNs from
RelB/ embryos. Thus, the absence of LTR-mediated
MAdCAM-1 upregulation in RelB/ stromal cells revealed
that MAdCAM-1 expression was a reliable readout for the
activation of the alternative pathway ex vivo. Therefore, we
extended our analyses in vivo by collecting mLNs from wt
embryos at day E15 and day E17. At day E15, we detected
ICAM-1int VCAM-1int cells but barely any ICAM-1high
VCAM-1high cells (Fig. 5B). Nevertheless, at day E17, part of
the pool of ICAM-1int VCAM-1int cells committed to the
ICAM-1high VCAM-1high phenotype. Despite the fact that
both populations expressed LTR, only ICAM-1high VCAM-
1high cells were positive for MAdCAM-1. In particular, LTR
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FIG. 3. LTR defective for p100 processing is sequestered into the plasma membrane. (A) HEK 293T cells were transfected with three
differently tagged LTRs (HA, Flag, and Myc tagged), and double immunoprecipitations were performed to analyze the trimerization of wt LTR
(see the supplemental material for details). (B) The same procedure as in panel A was applied for internal deletion mutants I 345–358 and I
359–368. (C) HEK 293T cells were transfected with wt LTR, I 345–358, I 359–368, and 389. The cross-linker DSP was used prior to
immunoprecipitation and immunoblotting of LTR under nonreduced (DTT) and reduced (DTT) conditions. (D) Flow cytometry analysis of
HEK 293 cells mock transfected or transfected with expression vector for wt LTR, LTR I 345–358, or LTR I 359–368 and stained for cell
surface LTR (nonpermeabilized [NP]) or cell surface and intracellular LTR (permeabilized [P]). MFI (mean fluorescence intensity) represents
the value of one measurement out of three independent experiments. (E) Localization of wt LTR, LTR I 345–358, and LTR I 359–368 in
HEK 293 cells. Arrows indicate the perinuclear compartment. (F) Cell fractionation of LTR into Triton X-100-soluble and -insoluble fractions
from HEK 293 cells transfected with the indicated LTR constructs.
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FIG. 4. Perinuclear location of LTR is a prerequisite for the recruitment of endogenous TRAF proteins and induction of p100 processing.
(A) Flow cytometry analysis of HEK 293 cells mock transfected or transfected with expression vector for LTR S wt, LTR S/I 345–358, or
LTR S/I 359–368 and stained for cell surface LTR (nonpermeabilized) or cell surface and intracellular LTR (permeabilized). MFI (mean
fluorescence intensity) represents the value of one measurement out of three independent experiments. (B) HeLa cells transiently transfected with
the indicated HA-tagged construct were stained for LTR (in red) and nuclei (DAPI). Arrows indicate the punctate perinuclear staining of LTR.
(C) HEK 293 cells were mock transfected or transfected with LTR expression vectors encoding either wt, I 345–358, I 359–368, or their signal
sequence (S)-defective counterpart. Immunoprecipitated LTR was analyzed by Western blotting for the recruitment of endogenous TRAF2 and
TRAF3. The asterisks represent the cross-reactivity with Ig heavy chains. (D) Extracts from cells transfected with signal sequence (S)-defective
mutants were used to analyze the processing of p100 by Western blotting.
4326 GANEFF ET AL. MOL. CELL. BIOL.
cell surface expression in the ICAM-1high VCAM-1high
MAdCAM-1 cell population was reduced compared to that
in ICAM-1int VCAM-1int MAdCAM-1 cells. However, this
decrease was not due to a down-modulation of LTR tran-
script since the mRNA levels of expression were similar in
ICAM-1int VCAM-1int and ICAM-1high VCAM-1high cells
(Fig. 5C). We conclude from these experiments that the acti-
vation of the alternative NF-B pathway in vivo correlates with
a downregulation of LTR cell surface expression.
LTR-induced stabilization of intracellular NIK and acti-
vation of the alternative NF-B pathway rely on dynamin-2
GTPase activity. We further analyzed the mechanisms that
control the internalization of endogenous LTR after binding
of its natural ligands. First, we performed flow cytometry anal-
yses on human epithelial colon carcinoma HT29 cells and
observed that the level of cell surface LTR dropped as soon
as 5 min after treatment with LT12 or LIGHT (Fig. 6A and
data not shown). This early internalization of ligand-bound
LTR was conserved across species, since treatment of MEFs
with an agonistic antibody resulted in a similar pattern of
LTR internalization (see Fig. S6A in the supplemental ma-
terial). We confirmed the internalization of activated LTR by
performing confocal analyses of HT29 cells treated for differ-
ent periods of time with an agonistic antibody to LTR. LTR
was associated with a shift from a cell membrane staining
(untreated cells) to a punctate pattern (LTR stimulated),
while the early endosome-associated protein EEA1 staining
showed the typical punctate profile (Fig. 6B). We observed
that, over time, activated LTR accumulated in early endo-
somes and colocalized with EEA1. Several routes of internal-
ization converge to early endosomes, and a role for AP2/clath-
rin complexes was highlighted for TNFR members such as
TNFR1 or Fas (44). Interestingly, we found that LTR is a
bona fide partner of the adaptor complex AP2. Indeed, we
observed that activation of LTR led to a fast recruitment of
the AP22 subunit, which was almost concomitant with
FIG. 5. Internalization of stromal LTR correlates with induction of MAdCAM-1. (A) RelB is necessary for a sustained induction of
MAdCAM-1 expression in E14 mLN organ culture treated with an agonistic antibody to LTR. Flow cytometry analysis of single cell suspensions
of wt (left panel) and RelB/ (right panel) E14 mLNs in organ cultures for 3 days. Percentages shown in histograms correspond to CD45 stromal
cells. Three different stromal cell populations were gated: ICAM-1neg VCAM-1neg (Ineg Vneg), Iint Vint, and Ihigh Vhigh. Expression levels of
MAdCAM-1 for each cell population are shown in histograms. (B) Emergence of the Ihigh Vhigh stromal organizer cells in mLNs. Flow cytometry
analysis of single cell suspensions of mLNs at E15 and E17 showing the recruitment of CD45 hematopoietic cells and the concomitant phenotypic
changes in the CD45 stromal cells. Percentages shown in the histogram correspond to CD45 stromal cells and CD45 hematopoietic cells. At
E15, the stromal cell population expressed low levels of ICAM-1 and VCAM-1 (Iint Vint cell population). These cells expressed LTR but were
MAdCAM-1 negative. At E17, the stromal cells have matured and some cells express high levels of ICAM-1 and VCAM-1 (Ihigh Vhigh cell
population, in red) and MAdCAM-1 but downregulated LTR cell surface expression. (C) The Iint Vint and Ihigh Vhigh cell populations expressed
the same levels of LTR mRNA. Iint Vint and Ihigh Vhigh stromal cell populations of mLNs at E18 were sorted and analyzed for LTR mRNA
expression by real-time PCR. Ratios of the gene of interest to the -actin gene are shown. Results are representative of at least 3 independent
experiments.
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TRAF3 recruitment (Fig. 6C; see also Fig. S6B). This result
prompted us to analyze the connection between the AP22
and LTR-mediated NF-B activation. Therefore, we ana-
lyzed the responsiveness of LTR-activated HeLa cells trans-
fected with either siRNA control or siRNA AP22. Despite a
potent inhibition of endogenous AP22 expression combined
with expression of a dominant negative rat AP22, neither
IB degradation nor p100 processing was altered following
FIG. 6. Dynamin-dependent internalization of LTR is required for the activation of the alternative but not the classical NF-B pathway.
(A) Flow cytometry analysis of cell surface LTR expression in untreated and LT12-treated HT29 cells. (B) Colocalization of LTR and EEA1
to early endosomes. HT29 cells were stimulated with an agonistic antibody to LTR for the indicated time prior to immunostaining. (C) Re-
cruitment of endogenous AP22 subunit to immunoprecipitated LTR. (D) Inducible ( Dox [doxycycline]) rat dominant negative (DN)
AP22-expressing HeLa cells transfected with control or siRNA AP22 and stimulated with an agonistic anti-LTR antibody. (E) HeLa cells
transfected with siRNA clathrin heavy chain (CHC) and treated as indicated for the assessment of IB degradation and p100 processing. (F) The
same cells were transfected with siRNA dynamin-2 and treated as in panel E for the analysis of classical and alternative NF-B pathways. (G) HeLa
cells were treated with the Smac mimetic CmpA prior to staining with the Duolink technology and the indicated antibodies. The endogenous
NIK/TRAF3 complex appears in red, and nuclei appear in blue (DAPI).
FIG. 7. The GTPase activity of dynamin-2 is involved in the induction of the processing of p100 in response to activated LTR. (A) HeLa cells
were incubated with DMSO (vehicle) or Dynasore (80 M) 1 h before stimulation with the agonist (ago) to LTR for the indicated time period.
Total cell extracts were analyzed by immunoblotting for the indicated proteins. (B and C) Experiments were conducted as for panel A with HT1080
and human primary fibroblasts, respectively. (D) HeLa cells were pretreated or not with Dynasore for 1 h followed by a brief stimulation with the
ago to LTR. Cell extracts were immunoprecipitated with an anti-LTR antibody prior to immunoblotting with anti-TRAF2. (E) The same
extracts as in panel A were analyzed for the phosphorylation and degradation of IB.
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LTR stimulation (Fig. 6D). Similar results were obtained
with siRNA CHC (Fig. 6E). Hence, LTR-mediated p100
processing appeared to be AP2/clathrin independent.
Since dynamin participates in clathrin-dependent as well as
clathrin-independent endocytosis, we extended our analysis by
using siRNA dynamin-2. Under these conditions, LTR-in-
duced NIK stabilization, phosphorylation, and depletion of
p100 were completely abrogated (Fig. 6F). Conversely, the
activation of the classical pathway remained intact since the
pattern of IB degradation was similar. Thus, although de-
pletion of dynamin-2 does not prevent recruitment of signaling
proteins to the cytosolic tail of LTR for the induction of the
classical NF-B pathway, the receptor is not able to alleviate
the constitutive degradation of NIK. Thus, we speculated that
NIK must be kept in check within an intracellular compart-
ment. To address this question, we used a method that allowed
us to observe endogenous NIK/TRAF3 within the cell. Since
NIK is constantly degraded by c-IAP1/2, we first pretreated or
not HeLa cells with the Smac mimetic compound A (CmpA)
for 2 h. This approach allowed us to stabilize NIK without
disrupting its binding to TRAF3. Then, using the Duolink
technology, we observed that endogenous NIK/TRAF3 com-
plex was physically localized within punctate cytosolic bodies
(Fig. 6G). Thus, it is likely that dynamin-2 participates in the
transport of activated LTR in close proximity to NIK/TRAF3
bodies to allow TRAF3 recruitment and activation of the al-
ternative NF-B pathway.
We next extended our analyses by using a noncompetitive
inhibitor of the GTPase activity of dynamin, named Dynasore
(32). We observed that preincubation of HeLa cells with
Dynasore fully abrogated the stabilization of NIK and the
processing of p100 in response to LTR stimulation (Fig. 7A).
These observations could be extended to other cell lines as well
as to human primary fibroblasts (Fig. 7B and C).
Conversely, Dynasore inhibited neither the early phase of
TRAF2 recruitment to activated LTR nor the activation of
the classical pathway since IB phosphorylation and degra-
dation were similar in control and Dynasore-treated cells (Fig.
7D and E).
Altogether, these results confirmed our findings using the
genetic approach with siRNA and revealed that the GTPase
activity of dynamin-2 is crucial for the induction of the alter-
native NF-B pathway.
TRAF3 degradation is secondary to LTR-mediated p100
processing. The current model is that TRAF3 recruitment and
polyubiquitination by c-IAP1/2 occur at the cytoplasmic mem-
brane-anchored receptor, leading to subsequent proteasomal
TRAF3 degradation and NIK-induced p100 processing (52,
60). However, we observed that LTR internalization is abso-
lutely required for the activation of the alternative NF-B
pathway. Thus, we hypothesized that TRAF3 might be tar-
geted for K48 polyubiquitination within the intracellular com-
partment. We established a system in which TRAF2, TRAF3,
NIK, and HA-tagged ubiquitin were transiently coexpressed
into 293T cells in the absence or presence of LTR S wt.
Following blockade of the proteasome, we were able to effi-
ciently immunoprecipitate, from SDS-denatured and rena-
tured protein extracts, equal amounts of TRAF3 and NIK, in
the absence and presence of LTR S wt (Fig. 8A). However,
when we probed the same membranes with an anti-ubiquitin
K48 antibody, we did not detect any K48-linked polyubiquiti-
nated TRAF3 adducts. Conversely, in the absence of LTR S
wt, we observed that NIK was constitutively polyubiquitinated.
Nevertheless, in the presence of LTR S wt, the level of
K48-linked polyubiquitinated NIK was drastically reduced
without a concomitant TRAF3 K48-linked polyubiquitination.
These results suggested that proteasomal degradation of
TRAF3 would not be the only mechanism regulating its steady
state. Indeed, blockade of the proteasome only marginally pre-
vented TRAF2 and TRAF3 degradation upon LTR stimula-
tion, despite a potent inhibition of IB degradation and p100
processing (Fig. 8B). Moreover, inactivation of c-IAP1 by
Smac mimetic (CmpA) did not prevent further TRAF3 deg-
radation upon costimulation of LTR (Fig. 8C). These results
indicated that other mechanisms might account for LTR-
mediated TRAF3 degradation. We next analyzed the role of
lysosomes for the degradation of TRAF2 and TRAF3 by using
two different inhibitors of vacuolar ATPase activity, such as
bafilomycin A1 and chloroquine. HeLa cells were treated for
different periods of time with an agonistic antibody to LTR in
the absence or presence of bafilomycin A1 or chloroquine, and
the phosphorylation and degradation of IB, as well as the
processing of p100, were analyzed by Western blotting. Under
both conditions, phospho-IB appeared as soon as 15 min
after stimulation followed by an almost complete degradation
of IB within 30 min. The efficiencies of p100 processing were
also comparable between untreated and bafilomycin A1- or
chloroquine-treated cells (Fig. 8D and data not shown). These
results indicate that LTR-mediated lysosomal degradation of
TRAF2 and TRAF3 is dispensable for the activation of both
the classical and the alternative NF-B pathway. Overall, our
results strongly suggest that internalized LTR displaces intra-
cellular TRAF3 from NIK, allowing its stabilization as previ-
ously proposed (41).
Altogether, we propose a model depicting ligand-bound
LTR complex outcomes and in which dynamin-dependent
FIG. 8. Intracellular LTR activates the alternative NF-B pathway independently of TRAF degradation. (A) HEK 293 cells were transiently
transfected () or not () with the indicated expression vectors. Cells were lysed in 1% SDS and diluted up to 0.1% prior to the first round of
immunoprecipitation (1st IP) with a control antibody (Ctrl Ab) or an anti-TRAF3 antibody. The immunoprecipitated material was analyzed by
immunoblotting for TRAF3 and K48-linked TRAF3. The supernatants from the 1st IP were incubated with control beads or anti-Flag-coated
beads. The immunoprecipitated materials were analyzed by immunoblotting for NIK and K48-linked ubiquitinated NIK. The asterisks represent
the cross-reactivity with Ig heavy chains. (B) HeLa cells were stimulated with the agonist (Ago) to LTR in the presence of DMSO (vehicle) or
the proteasome inhibitor MG132, and cell extracts were analyzed by immunoblotting for the indicated proteins. (C) HeLa cells were treated with
compound A (CmpA) or the Ago to LTR alone or in combination as indicated, and the indicated proteins were analyzed by immunoblotting.
(D) HeLa cells were stimulated as indicated with the Ago to LTR in the absence (vehicle) or presence of bafilomycin A1. Total cell extracts were
analyzed by Western blotting for the indicated proteins.
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internalization uncouples the activation of the classical and the
alternative NF-B pathways (Fig. 9).
DISCUSSION
The biological functions fulfilled by members of the TNFR
family rely on distinct signaling pathways for which recruitment
of different TRAF proteins plays key roles. In this study, we
identified an uncharacterized TRAF binding site spanning
amino acid 345 to 368 of human LTR. We showed that this
region was as important as the triad D390/D391/E393 of LTR
for the recruitment of TRAF2 or TRAF3 in GST pulldown
experiments (29). Of note, the primary sequence of amino
acids 345 to 368 did not reveal any features of canonical
TRAF2 or TRAF3 binding sites. Interestingly, other uncon-
ventional TRAF binding sites have also been characterized for
TNFR2 (PLGVPDAGMKPS) and NIK (ISIIAQA), for which
the recruitment of TRAF2 and TRAF3 appeared to be indirect
and direct, respectively (16, 19, 30). Our data revealed that the
affinity of the two TRAF binding sites of LTR might fluctuate
according to the oligomerization status of LTR. Indeed, de-
letion of one of the two TRAF binding sites was sufficient to
disrupt the recruitment of TRAF2 and TRAF3 to LTR if
expressed as a GST fusion protein. However, when LTR was
expressed as a native protein in eukaryotic cells, the region 345
to 368 retained some TRAF3 binding activity despite the de-
letion of the other TRAF binding site. It is reasonable to
suggest that aggregation of LTR increases the local concen-
tration of LTR, allowing it to increase its avidity toward
TRAF3. The outcome of TRAF proteins following recruit-
ment to TNFR varies from one receptor to another, involving
degradation through either the proteasome or into lysosomes,
as well as cellular relocalization to restricted cellular compart-
ments (48). Recently, it was proposed that LTR-mediated
TRAF3 proteasomal degradation was required for stabilizing
and accumulating NIK (41). However, under conditions for
which overexpressed LTR solely induced p100 processing, we
did not observe an accumulation of K48-linked polyubiquiti-
nated TRAF3, while the pool of K48-linked polyubiquitinated
NIK was strongly reduced. Furthermore, it was shown that
LTR-mediated depletion of TRAF3 was required not only
for the induction of the alternative pathway but also for the
FIG. 9. Model of LTR trafficking and NF-B activation. The binding of LT12 to LTR leads to its trimerization. This event allows a fast
recruitment of TRAF proteins through the bipartite TRAF binding site (amino acids 389 to 395 in blue and 345 to 368 in red). This process then
connects the receptor to the induction of IB degradation by the proteasome (classical NF-B pathway). In the meantime, the complex AP2 in
association with clathrin regulates an NF-B-independent function of LTR. While LT12 accumulates at the cell surface of inducer cells, LTR
trimers form clusters on targeted cells. This process likely triggers the internalization of LTR, which relies on the cytosolic region 345 to 368 and
the presence of dynamin-2. Endocytic vesicles released from the plasma membrane expose the tail of LTR toward the cytosol. This event allows
LTR to compete with intracellular NIK for the binding of its inhibitory complex TRAF3/TRAF2/c-IAP1/2. As a consequence, the constitutive
proteasomal degradation of NIK (dashed line) is alleviated. Thus, NIK accumulates (solid line) and activates IKK, and both events trigger the
processing of p100 and the generation of p52/RelB. TRAF3/TRAF2/c-IAP1/2 complex is then degraded into lysosomes.
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classical NF-B pathway in MEFs, as well as in some colon
epithelial cell lines (4, 59). Thus, proteasomal degradation of
TRAF3 is associated not only with NIK stabilization. This
statement can be also extended to signaling pathways down-
stream of CD40. Indeed, CD40-induced K48-linked polyubiq-
uitination and proteasomal degradation of TRAF3 are strictly
dependent on TRAF2 and c-IAP1/2 (21, 35, 52, 60). Based on
these findings, a model had been proposed in which activated
CD40 recruits TRAF2/TRAF3–c-IAP1/2 at the cell surface for
promoting TRAF3 proteasomal degradation and NIK stabili-
zation (52, 60). However, CD40-mediated K48-linked poly-
ubiquitination and proteasomal degradation of TRAF3 are
also required prior to cell membrane release of a MEKK1-
containing complex that activates Jun N-terminal protein ki-
nase (JNK) (34). Again, c-IAP1/2-mediated TRAF3 polyubiq-
uitination is engaged in two distinct pathways involving
MEKK1 and NIK. Therefore, assessing K48-linked TRAF3
polyubiquitination is not a readout strictly associated with an
activation of NIK. Overall, TRAF3 appears to be a multitask
protein that acts mainly as an inhibitor. It is likely that different
pools of TRAF3-containing complexes exist, and according to
the cell type and the duration of stimulation, TRAF3 is re-
cruited and degraded at different locations to activate distinct
pathways. We further observed that lymphotoxin-induced
TRAF2 and TRAF3 degradation also occurred in the lyso-
somal compartment. However, potent inhibition of TNFR-
mediated lysosomal TRAF degradation did not alter the extent
of p100 processing, suggesting that this type of degradation is
likely secondary to NIK stabilization.
Internalization of TNFR has been mainly considered a
mechanism participating in recycling and/or degradation. In
this study, we identified a new function assigned to LTR
trafficking, that is, the activation of the alternative NF-B path-
way. We found that toward lymphotoxin 12-induced mesen-
teric lymph node stromal cell maturation, internalization of
LTR correlated with RelB-induced MAdCAM-1 expression.
Similarly, ligand-induced down-modulation of cell surface
LTR has been observed in other settings, such as in myeloid
dendritic cell (DC) homeostasis, which is strictly dependent on
the alternative pathway, or SCS (subcapsular sinus) macro-
phage differentiation (23, 40, 55). Interestingly, we found that
internalization of LTR uncouples the activation of the alter-
native NF-B pathway from the classical NF-B pathway,
probably reflecting the requirement of different adaptor pro-
teins. This is reminiscent of the signaling pathways emerging
from TLR4 for which TIRAP/MyD88 and TRAM/TRIF com-
plexes regulate the proinflammatory and type I interferon re-
sponses from the plasma membrane and endosomes, respec-
tively (24).
Other biological functions have been assigned to internal-
ized TNFR family members. Indeed, TNFR1 also activates the
classical NF-B from the cell surface, but its internalization is
rather associated with TNF--induced cell death (43). This
process relies on a cytosolic region named the TRID domain,
which contains a consensus YXX motif that is targeted by the
adaptor complex AP2 for sorting activated TNFR1 to endo-
somes (43). We have also detected an interaction between AP2
and activated LTR. Unlike TNFR1, our bioinformatics anal-
yses of LTR did not reveal any consensus YXX motif.
Nevertheless, we found a dileucine motif at position 299 of
human LTR, which probably recruits AP2 through the bind-
ing of the 2 subunit (27). However, we showed that deletion
of the region encompassing this AP2 site did not alter the
induction of the processing of p100, which is consistent with
the fact that clathrin is dispensable for the activation of the
alternative NF-B pathway. Thus, AP2 may control LTR
internalization for the control of its half-life at the cell surface,
its recycling, or a yet-undefined function.
The signaling pathways linked to TNFR internalization have
been probably overlooked. Indeed, internalization of CD40
was reported to regulate the transcription of BAFF but also to
allow the interaction with c-Rel for promoting B cell lym-
phoma proliferation (31, 61). Whether LTR internalization
controls nuclear functions is a possible scenario and is under
investigation. Interestingly, ligand-dependent or -independent
LTR internalization might be linked to cancer progression.
Indeed, we showed that dynamin-dependent internalization of
LTR is required for NIK stabilization, and exacerbated ac-
cumulation of NIK has been reported in hematopoietic as well
as nonhematopoietic cancer cells (50). For instance, liver-spe-
cific LT/LT expression leads to hepatitis-induced hepatocel-
lular carcinoma development and this phenotype can be re-
versed when mice are treated with Fc-LTR recombinant
decoy receptors (18). Conversely, in LTR-expressing mela-
noma cells, activation of NIK is driven in a ligand-independent
way (12). In this particular case, the use of decoy LTR would
be useless and other strategies should be envisioned for pre-
venting LTR-mediated cell proliferation. The development
of molecules that specifically block LTR internalization, or
other receptors, might be a promising research avenue for
inflammatory disorders and cancer treatment.
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